Barclays
ANIP icon

Barclays’s ANI Pharmaceuticals ANIP Stock Holding History

Barclays’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-2,000
Closed -$90K – 6986
2018
Q4 		$90K Sell
2,000
-200
-9% -$10.5K ﹤0.01% 5109
2018
Q3 		$124K Buy
2,200
+2,000
+1,000% +$122K ﹤0.01% 5368
2018
Q2 		$13K Sell
200
-400
-67% -$25K ﹤0.01% 6398
2018
Q1 		$35K Sell
600
-100
-14% -$6.35K ﹤0.01% 6141
2017
Q4 		$45K Buy
700
+600
+600% +$37.3K ﹤0.01% 5815
2017
Q3 		$5K Hold
100
– – ﹤0.01% 6395
2017
Q2 		$5K Sell
100
-1,000
-91% -$48.2K ﹤0.01% 6220
2017
Q1 		$54K Hold
1,100
– – ﹤0.01% 5291
2016
Q4 		$67K Buy
+1,100
New +$67.3K ﹤0.01% 4983
2015
Q2 		– Sell
-95,800
Closed -$5.94M – 6996
2015
Q1 		$5.94M Buy
+95,800
New +$5.83M 0.01% 1429
2014
Q1 		– Sell
-336
Closed -$7K – 7556
2013
Q4 		$7K Hold
336
– – ﹤0.01% 7085
2013
Q3 		$3K Sell
336
-23
-6% -$166 ﹤0.01% 7095
2013
Q2 		$2K Buy
+359
New +$2.51K ﹤0.01% 7511

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Barclays's ANIP Position: Q2 2026 in Review

Barclays increased its ANI Pharmaceuticals (ANIP) stake by 77% in Q2 2026, buying an estimated $4.19M and bringing the position to 119,707 shares worth $9.91M. The position accounts for ﹤0.01% of the portfolio, ranked #1483.

Barclays first reported a position in ANIP in Q2 2013 and has held it in 53 quarters since. The position peaked at $12M in Q2 2025. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Barclays held 119,707 shares of ANI Pharmaceuticals worth $9.91M as of Q2 2026.
  • Barclays bought 52,260 ANI Pharmaceuticals shares in Q2 2026, an estimated $4.19M.
  • ANI Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1483 holding.
  • Barclays first reported a position in ANI Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Barclays's ANI Pharmaceuticals position peaked at $12M in Q2 2025.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.